Wellington Partners announced the final close of Wellington Partners Life Science Fund V at €210 million ($233.69 million). The fifth-generation fund, which invests in early- and growth stage life science companies, finished well above its €150 million target.
The fund will hone in on companies ranging from biotechnology platforms, therapeutics, medical devices, diagnostics and digital medicine. Similar to its predecessor, it will seek opportunities in German speaking parts of Europe, while still considering those in North America or Asia.
Limited partners know to have contributed investment include KfW Capital, Talanx and US-based UTIMCO, the University of Texas/Texas A&M Investment Company.